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Abstract
Cutaneous mastocytosis is characterized by increased numbers of
skin mast cells that release mediators causing pruritus, urticaria, and
flushing. Most pediatric mastocytosis patients exhibit the pattern of
urticaria pigmentosa, which typically appears during the first two years
of life and resolves spontaneously in late adolescence. However, while
the disease is active, patients are frequently symptomatic and
uncomfortable, which justifies symptomatic treatment. We report 2
patients, a 14-month-old girl and a 26-month-old boy, with localized
cutaneous erythematous lesions with a positive Darier sign. In each, a
punch biopsy confirmed the diagnosis of mastocytosis. Treatment was
instituted with pimecrolimus cream twice a day and oral antihistamine.
An almost complete response was achieved after 4 months of therapy in
both patients, with no clinical evidence of recurrence after 4 years and 2
years of follow-up, respectively. In children, the treatment of
mastocytosis is directed primarily to avoiding potential mast cell
degranulating agents and alleviating symptoms. Topical calcineurin
inhibitors act by inhibiting T-cell activation and cytokine release; they
may suppress mast cell- mediated reactions by reducing their
degranulation. These two cases suggest that in localized cutaneous
mastocytosis they are a safe and efficacious alternative to topical steroid
therapy.
Introduction
Mastocytosis represents a spectrum of rare clinical disorders
characterized by an increase in tissue mast cells [1, 2]. It is traditionally
divided into cutaneous mastocytosis and systemic mastocytosis.
Cutaneous mastocytosis can be divided into four clinical variants:
urticaria pigmentosa, solitary mastocytoma, diffuse cutaneous
mastocytosis, and telangiectasia macularis eruptive perstans [3].
The onset of mastocytosis can occur from birth to adulthood, but
childhood disease is more common and often affects only the skin. Most
pediatric mastocytosis cases exhibit the form of urticaria pigmentosa that
typically appears during the first two years of life and resolves
spontaneously in late adolescence [1, 2].
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Mutations of the c-kit proto-oncogen, coding for the
transmembrane receptor kit of the stem cell growth factor, have been
implicated in the etiology of mastocytosis. The stem cell growth factor
has a role in maturation, proliferation, and activation of mast cells, which
produce tryptase [4]. Total serum tryptase correlates with the extent of
the mast cell disease [5].
Case report
Figure 1a Figure 1b
Figure 1a. Patient 1: Erythematous plaque on the right upper arm
Figure 1b. Patient 1: Skin biopsy from an erythematous plaque on the upper
limb. The mast cells have a perivascular location in the upper dermis in the
vicinity of an ectatic vessel. (H&E, x40)
Figure 1c Figure 1d
Figure 1c. Patient 1: The cytoplasmic granules characteristic of mast cells
are revealed by the Giemsa stain (x40)
Figure 1d. Patient 1: Significant improvement after 4 months of treatment
We report 2 patients with cutaneous mastocytosis.
Patient 1 is a 14-month-old girl with a limited cutaneous
erythematous plaque located on the right upper arm, which showed a
positive Darier sign (urtication induced by stroking lesions) (Figure 1a).
The plaque appeared in the first 4 months of life.
Patient 2 is a 26-month-old boy with erythematous papules
located on the right lower back that evolved over several months
(Figure 2a).
The personal and family histories of both patients were non-
contributory. Systemic symptoms, including abdominal pain, diarrhea,
palpitations, syncope, bone pain, or weigh loss were absent in both
children. Total serum tryptase was normal in both and the clinical
diagnosis was mastocytosis in both cases. A punch biopsy was
performed in each patient that revealed telangiectasia and perivascular
mast cells in H&E. Giemsa staining confirmed the presence of granules
(Figures 1b, 1c, 2b, and 2c).
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Figure 2a Figure 2b
Figure 2a. Patient 2: Erythematous plaque at the right lower back
Figure 2b. Patient 2: Skin biopsy showing a dense mast cell infiltrate with
perivascular and interstitial location. Notice the increased deposit of melanin
in basal keratinocytes, which is responsible for the hyperpigmented
appearance (H&E, x40)
Figure 2c Figure 2d
Figure 2c. Patient 2: The Giemsa stain highlights the cytoplasmic granules
typical of mast cells (x40).
Figure 2d. Patient 2: Complete resolution after 6 months of treatment.
Treatment was instituted with pimecrolimus cream (twice a day
during three months, followed by once a day until at least 2 months after
clinical resolution) and oral antihistamine (loratadine, 5 mg once a day).
Almost complete resolution was achieved after 4 months of therapy in
both patients (Fig 1d and 2d). Patient 1 used pimecrolimus for a total of
9 months and patient 2 for a total of 6 months. During follow-up there
was no clinical evidence of recurrence after 4 years in patient 1 and 2
years in patient 2.
Discussion
The prognosis of pediatric mastocytosis is good; the children are
usually without systemic involvement and complete spontaneous
resolution is common in months to years [1, 3]. However, while the
disease is active, patients are frequently symptomatic and
uncomfortable, which justifies symptomatic treatment [4]. The
occurrence of pruritus, urtication and flushing caused by mediator
release can be reduced by avoiding potential mast cell degranulating
agents, such as certain food and drugs, exercise, heat, and friction.
Because histamine is the single most important mediator involved,
antihistamines are commonly used as first-line treatment to alleviate
symptoms. Topical steroids have been proposed but the outcome is
variable [6].
The topical calcineurin inhibitors (TCI) have substantially improved
the treatment of atopic dermatitis and also have a beneficial effect in
other inflammatory dermatoses such as seborrheic dermatitis, genital
lichen sclerosus, intertriginous psoriasis, cutaneous lupus erythematosus,
autoimmune bullous dermatosis, vitiligo, graft-versus-host disease, and
Netherton syndrome [7].
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Netherton syndrome [7].
Topical calcineurin inhibitors (TCI) act by inhibiting T-cell
activation and cytokine release, but they also reduce pruritus and
erythema, which canÕt be explained by T-cell interactions alone. On the
other hand, there is evidence they transiently induce neuropeptide
release, namely substance P and calcitonin gene-related peptide, that
bind to mast cells leading to their degranulation. This explains the
abnormal transient burning, stinging, and itching at the beginning of
therapy with TCI [8]. However, in an experimental model, the
continuous application of topical tacrolimus suppresses mast cell-
mediated reactions by reducing their degranulation rather than by
decreasing their number [9].
Although pediatric cutaneous mastocytosis may resolve
spontaneously, the quick and sustained response of these two cases
corroborates the effectiveness of the use of TCI in the treatment of mast
cell-dependent diseases such as mastocytosis. Furthermore, we have
also used TCI for the treatment of four more children with urticaria
pigmentosa, with the same regimen (pimecrolimus cream twice a day
during three months followed by application once a day, until 2 months
after clinical resolution and oral antihistamine - loratadine, 5 mg once a
day). In these four patients (all males, ages ranging from 7 to 16
months), all with normal serum tryptase, significant improvement was
achieved 3 months after starting treatment (unpublished data).
There are few reports of cutaneous mastocytosis treated with TCI
[10, 11]. Concerning their advantages in relation to topical steroids, we
emphasize the more selective mechanism of action, the absence of skin
atrophy, and the lack of significant systemic absorption [7]. With this
profile they could be a low toxicity first line therapy for the symptoms of
cutaneous mastocytosis,and an alternative to topical corticosteroids.
However, because the majority of children who develop urticaria
pigmentosa before the age of two years resolve spontaneously, large-
scale randomized placebo-controlled studies are needed to clarify the
role of TCI in the treatment of cutaneous mastocytosis.
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